HighTide Therapeutics Inc

02511

Company Profile

  • Business description

    HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

  • Contact

    Building D, Guangdong
    Floor 9 to 10, Fubao Community, Futian District
    Shenzhen-Hong Kong Science and
    Technology Innovation Cooperation Zone
    Shenzhen518112
    CHN

    T: +86 75526626253

    https://www.hightidetx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    57

Stocks News & Analysis

stocks

We remove our Moat Rating from ASX listed share

Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks

Best sustainable companies to own in 2026

We believe these companies’ strong ESG management practices give them a long-term advantage.
stocks

New data centre deal for ASX listed REIT

New parternship adds to a growing data centre pipeline in fiscal 2026.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,034.702.20-0.02%
CAC 408,201.005.790.07%
DAX 4024,675.23135.890.55%
Dow JONES (US)48,382.39319.100.66%
FTSE 1009,969.9418.800.19%
HKSE26,347.248.770.03%
NASDAQ23,235.636.36-0.03%
Nikkei 22551,832.801,493.322.97%
NZX 50 Index13,587.2338.810.29%
S&P 5006,858.4712.970.19%
S&P/ASX 2008,728.602.600.03%
SSE Composite Index4,023.4254.581.38%

Market Movers